Harrow (NASDAQ:HROW) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Harrow (NASDAQ:HROW) in a research report report published on Monday,Benzinga reports. They currently have a $64.00 price target on the stock.

A number of other research firms have also issued reports on HROW. Cantor Fitzgerald started coverage on Harrow in a report on Friday, July 11th. They issued an “overweight” rating and a $76.00 target price for the company. Craig Hallum increased their price target on Harrow from $54.00 to $64.00 and gave the company a “buy” rating in a research report on Tuesday, September 23rd. Zacks Research downgraded Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. B. Riley raised their target price on shares of Harrow from $65.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, September 23rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday, September 24th. Seven analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $67.83.

Harrow Trading Up 2.8%

NASDAQ HROW opened at $48.40 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -193.60 and a beta of 0.33. The firm has a 50 day simple moving average of $38.70 and a 200-day simple moving average of $31.68. Harrow has a one year low of $20.85 and a one year high of $59.23.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The firm had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

A number of institutional investors and hedge funds have recently bought and sold shares of HROW. Quarry LP purchased a new position in shares of Harrow during the first quarter worth about $32,000. Raymond James Financial Inc. acquired a new position in Harrow during the second quarter worth approximately $48,000. State of Wyoming purchased a new stake in Harrow in the first quarter valued at approximately $97,000. Tower Research Capital LLC TRC lifted its stake in Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Harrow in the 1st quarter valued at $149,000. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.